Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world persistence with dupilumab among adults with atopic dermatitis.
Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, Zhang H, Chen Z, Chen C, Korotzer A, Sierka D, Fenton MC, Kaur M, Jalbert JJ. Silverberg JI, et al. Among authors: mastey v. Ann Allergy Asthma Immunol. 2021 Jan;126(1):40-45. doi: 10.1016/j.anai.2020.07.026. Epub 2020 Jul 31. Ann Allergy Asthma Immunol. 2021. PMID: 32739313 Free article.
Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.
Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suárez-Fariñas M, Gadkari A. Simpson EL, et al. Among authors: mastey v. JAMA Dermatol. 2018 Aug 1;154(8):903-912. doi: 10.1001/jamadermatol.2018.1572. JAMA Dermatol. 2018. PMID: 29971354 Free PMC article.
Correction to: The Patient Matters in the End(point).
Griffiths P, Rofail D, Lehner R, Mastey V. Griffiths P, et al. Among authors: mastey v. Adv Ther. 2022 Nov;39(11):4853. doi: 10.1007/s12325-022-02309-9. Adv Ther. 2022. PMID: 36083427 Free PMC article. No abstract available.
The Patient Matters in the End(point).
Griffiths P, Rofail D, Lehner R, Mastey V. Griffiths P, et al. Among authors: mastey v. Adv Ther. 2022 Nov;39(11):4847-4852. doi: 10.1007/s12325-022-02271-6. Epub 2022 Aug 5. Adv Ther. 2022. PMID: 35930125 Free PMC article.
Cost-effectiveness of PCSK9 Inhibitor Therapy.
Mastey V, Johnstone BM. Mastey V, et al. JAMA. 2016 Nov 22;316(20):2151-2152. doi: 10.1001/jama.2016.16286. JAMA. 2016. PMID: 27893122 No abstract available.
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Rischin D, et al. Among authors: mastey v. J Immunother Cancer. 2021 Aug;9(8):e002757. doi: 10.1136/jitc-2021-002757. J Immunother Cancer. 2021. PMID: 34413166 Free PMC article. Clinical Trial.
37 results